Optimization of Assay to Analyze Biofilm development and Identify Antimicrobial Agents
by Robert Buckheit III
February 3, 2016
The ImQuest scientific team has optimized a high-throughput protocol to study biofilm development and the effect of antimicrobial agents on biofilm formation, and these data are available in our recently published white paper Biofilm Protocol Optimization with Gram-Positive Cocci. This assay complements the services of our MicroSENS program, which already include our in vivo mouse models of bacterial infection (Neutropenic Thigh model and Peritonitis-Sepsis Model of MRSA Infection), and our antibiotic-resistance microbe panel for the evaluation of new antimicrobial agents, especially those targeting ESKAPE pathogens.
Treatment of biofilm-based bacterial infection is especially challenging because microbes in biofilms are highly resistant to antimicrobial treatment and tenaciously bind to surfaces. According to the Centers for Disease Control and Prevention, biofilms are implicated in more than 80 percent of chronic inflammatory and infectious diseases caused by bacteria. Given the continued evolution of antibiotic resistance and the inherent resistance of bacteria in biofilms to antibiotics, the development of antibiotics that target biofilm formation has become increasingly important.
Learn More about our method to screen antimicrobial agents for their effects on biofilm formation and dispersal.Return to the Blog